Know Cancer

forgot password

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL

Phase 2
18 Years
Open (Enrolling)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Thank you

Trial Information

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL

Inclusion Criteria:

- Histologically confirmed,CLL/SLL, documented relapsed or refractory disease after at
least one prior chemotherapy regimen.

- In cases of SLL, patients must have at least one bidimensionally measurable lesion at
least ≥1.5 cm measured in one dimension.

- ECOG performance status of 0-2 at study entry

- Laboratory test results within these ranges: ANC <=1500/μL, Platelet count <=
100,000/μL. Patients with ANC <1500/μL or plt <100,000/μL with splenomegaly or
extensive bone marrow involvement as the etiology for their cytopenias are eligible.

- creatinine clearance of >60 mL/min as determined by the Cockcroft-Gault calculation.

- Total bilirubin <= 2X upper limit laboratory normal (ULN). Patients with
non-clinically significant elevations of bilirubin due to Gilbert's disease are not
required to meet these criteria.

- Serum transaminases AST (SGOT) and ALT (SGPT) <=5x ULN, Serum alkaline phosphatase ≤5

- Disease free of prior malignancies for ≥ 2 years with the exception of basal or
squamous cell skin carcinoma, carcinoma "in situ" of the breast or cervix, or
localized prostate cancer (treated definitively with hormone therapy, radiotherapy,
or surgery).

- Patients may have received prior therapy with bendamustine or lenalidomide, but must
not have disease that is refractory to bendamustine or lenalidomide.

- Prior therapy with rituximab is permitted, even in the setting of rituximab
refractory disease.

Exclusion Criteria:

- Has received >5 lines of prior therapy for their disease. Re-treatment with an
identical regimen does not count as a new regimen.

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form or comply with the
protocol treatment.

- Pregnant or breast feeding females. Lactating females must agree not to breast feed
while taking lenalidomide.

- Prior history or current evidence of central nervous system or leptomeningeal

- Use of any other experimental drug or therapy within 28 days of baseline.

- Known hypersensitivity to thalidomide.

- The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or similar drugs.

- Known to be positive for HIV or infectious hepatitis, type B or C.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival

Outcome Time Frame:

March 2017

Safety Issue:


Principal Investigator

Julie Chang, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Wisconsin, Madison


United States: Institutional Review Board

Study ID:




Start Date:

October 2009

Completion Date:

March 2017

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • CLL
  • SLL
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lymphoma



Marshfield Clinic Marshfield, Wisconsin  54449
Medical College of Wisconsin Milwaukee, Wisconsin  53226
Waukesha Memorial Hospital Waukesha, Wisconsin  53188
Bellin Memorial Hospital Green Bay, Wisconsin  54301
Oconomowoc Memorial Hospital Oconomowoc, Wisconsin  53066
Riverview Hospital Wisconsin Rapids, Wisconsin  54494
University of Wisconsin Carbone Cancer Center Madison, Wisconsin  53792-5669
St Vincent Regional Cancer Center Green Bay, Wisconsin  54301
Mercy Health System Heme/Onc Janesville, Wisconsin  53548
Gundersen Clinic LaCrosse, Wisconsin  54601